These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 26049932)
41. The effect of interferon-alpha2b on an in vitro model Dupuytren's contracture. Sanders JL; Dodd C; Ghahary A; Scott PG; Tredget EE J Hand Surg Am; 1999 May; 24(3):578-85. PubMed ID: 10357539 [TBL] [Abstract][Full Text] [Related]
42. Screening of potential prodrugs on cells derived from Dupuytren's disease patients. Kraljevic Pavelic S; Bratulic S; Hock K; Jurisic D; Hranjec M; Karminski-Zamola G; Zinic B; Bujak M; Pavelic K Biomed Pharmacother; 2009 Sep; 63(8):577-85. PubMed ID: 19010640 [TBL] [Abstract][Full Text] [Related]
43. Cryptotanshinone downregulates the profibrotic activities of hypertrophic scar fibroblasts and accelerates wound healing: A potential therapy for the reduction of skin scarring. Li Y; Shi S; Gao J; Han S; Wu X; Jia Y; Su L; Shi J; Hu D Biomed Pharmacother; 2016 May; 80():80-86. PubMed ID: 27133042 [TBL] [Abstract][Full Text] [Related]
44. Feedback inhibition of high TGF-beta1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts. Wong M; Mudera V J Hand Surg Br; 2006 Oct; 31(5):473-83. PubMed ID: 16875762 [TBL] [Abstract][Full Text] [Related]
45. First identification of resident and circulating fibrocytes in Dupuytren's disease shown to be inhibited by serum amyloid P and Xiapex. Iqbal SA; Hayton MJ; Watson JS; Szczypa P; Bayat A PLoS One; 2014; 9(6):e99967. PubMed ID: 24933153 [TBL] [Abstract][Full Text] [Related]
46. N-acetyl-L-cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren's disease by blunting TGF-beta signalling. Kopp J; Seyhan H; Müller B; Lanczak J; Pausch E; Gressner AM; Dooley S; Horch RE J Cell Mol Med; 2006; 10(1):157-65. PubMed ID: 16563228 [TBL] [Abstract][Full Text] [Related]
47. Fibronectin filaments and actin microfilaments are organized into a fibronexus in Dupuytren's diseased tissue. Tomasek JJ; Haaksma CJ Anat Rec; 1991 Jun; 230(2):175-82. PubMed ID: 1867394 [TBL] [Abstract][Full Text] [Related]
48. The effect of 5-fluorouracil on Dupuytren fibroblast proliferation and differentiation. Jemec B; Linge C; Grobbelaar AO; Smith PJ; Sanders R; McGrouther DA Chir Main; 2000 Feb; 19(1):15-22. PubMed ID: 10777424 [TBL] [Abstract][Full Text] [Related]
49. Contraction of collagen lattices by cells from Dupuytren's nodules. Tarpila E; Ghassemifar MR; Wingren S; Agren M; Franzén L J Hand Surg Br; 1996 Dec; 21(6):801-5. PubMed ID: 8982933 [TBL] [Abstract][Full Text] [Related]
50. Verteporfin ameliorates fibrotic aspects of Dupuytren's disease nodular fibroblasts irrespective the activation state of the cells. Puerta Cavanzo N; Riesmeijer SA; Holt-Kedde IL; Werker PMN; Piersma B; Olinga P; Bank RA Sci Rep; 2022 Aug; 12(1):13940. PubMed ID: 35977978 [TBL] [Abstract][Full Text] [Related]
51. Responsiveness of Dupuytren's disease fibroblasts to 5 alpha-dihydrotestosterone. Pagnotta A; Specchia N; Soccetti A; Manzotti S; Greco F J Hand Surg Am; 2003 Nov; 28(6):1029-34. PubMed ID: 14642522 [TBL] [Abstract][Full Text] [Related]
52. Genome-wide analysis using exon arrays demonstrates an important role for expression of extra-cellular matrix, fibrotic control and tissue remodelling genes in Dupuytren's disease. Forrester HB; Temple-Smith P; Ham S; de Kretser D; Southwick G; Sprung CN PLoS One; 2013; 8(3):e59056. PubMed ID: 23554969 [TBL] [Abstract][Full Text] [Related]
53. Circulating inflammatory cytokines alter transcriptional activity within fibrotic tissue of Dupuytren's disease patients. Wang ML; Rajpar I; Ruggiero NA; Fertala J; Steplewski A; Beredjiklian PK; Rivlin MR; Chen Y; Feldman GJ; Fertala A; Tomlinson RE J Orthop Res; 2022 Mar; 40(3):738-749. PubMed ID: 33913534 [TBL] [Abstract][Full Text] [Related]
54. Regulation of expression of alpha-smooth muscle actin in cells of Dupuytren's contracture. Hindman HB; Marty-Roix R; Tang JB; Jupiter JB; Simmons BP; Spector M J Bone Joint Surg Br; 2003 Apr; 85(3):448-55. PubMed ID: 12729127 [TBL] [Abstract][Full Text] [Related]
55. [Pathogenesis of Dupuytren's contracture--a review]. Koźma EM; Olczyk K; Bobiński R; Kasperczyk M; Szpyra K Chir Narzadow Ruchu Ortop Pol; 2002; 67(1):73-9. PubMed ID: 12087679 [TBL] [Abstract][Full Text] [Related]
56. Dupuytren's disease: comparative growth dynamics and morphology between cultured myofibroblasts (nodule) and fibroblasts (cord). Vande Berg JS; Gelberman RH; Rudolph R; Johnson D; Sicurello P J Orthop Res; 1984; 2(3):247-56. PubMed ID: 6491814 [TBL] [Abstract][Full Text] [Related]
57. Increased CCT-eta expression is a marker of latent and active disease and a modulator of fibroblast contractility in Dupuytren's contracture. Satish L; O'Gorman DB; Johnson S; Raykha C; Gan BS; Wang JH; Kathju S Cell Stress Chaperones; 2013 Jul; 18(4):397-404. PubMed ID: 23292503 [TBL] [Abstract][Full Text] [Related]
58. Intracellular actin as a marker for myofibroblasts in vitro. Foo IT; Naylor IL; Timmons MJ; Trejdosiewicz LK Lab Invest; 1992 Dec; 67(6):727-33. PubMed ID: 1460863 [TBL] [Abstract][Full Text] [Related]
59. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease. Ulrich D; Ulrich F; Piatkowski A; Pallua N Arch Orthop Trauma Surg; 2009 Nov; 129(11):1453-9. PubMed ID: 18758795 [TBL] [Abstract][Full Text] [Related]
60. Cell behavior and cell-matrix interactions of human palmar aponeurotic cells in vitro. Quaglino D; Bergamini G; Croce A; Boraldi F; Barbieri D; Caroli A; Marcuzzi A; Tiozzo R; Ronchetti IP J Cell Physiol; 1997 Dec; 173(3):415-22. PubMed ID: 9369955 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]